Global Asthma Biologics Market Growth (Status and Outlook) 2026-2032
The global Asthma Biologics market size is predicted to grow from US$ 7056 million in 2025 to US$ 14458 million in 2032; it is expected to grow at a CAGR of 10.7% from 2026 to 2032.
Asthma Biologics refers to marketed monoclonal antibody medicines used as add-on maintenance therapy for patients with moderate-to-severe or severe asthma that remains uncontrolled despite optimized inhaled controller treatment. These therapies act on defined immune pathways involved in allergic and type 2 airway inflammation, principally immunoglobulin E, interleukin-5, interleukin-5 receptor alpha, interleukin-4 receptor alpha and thymic stromal lymphopoietin. Commercial products are supplied mainly as subcutaneous injections in vials, prefilled syringes or other ready-to-use presentations, while intravenous infusion remains relevant for selected anti-IL-5 therapy. Treatment selection is guided by clinical phenotype and biomarkers, including allergic sensitization, serum IgE, blood eosinophils, exacerbation history, oral corticosteroid dependence and broader type 2 inflammatory characteristics. The research scope covers approved and commercially available omalizumab, omalizumab alfa, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab and depemokimab products across adult, adolescent and pediatric asthma settings, with analysis organized by molecule, immune target, clinical phenotype and administration route.
Key Findings
The average gross profit margin of this product is 84%
Severe uncontrolled asthma remains the core commercial treatment setting
Type 2 inflammation underpins most approved biologic treatment pathways
Subcutaneous administration dominates marketed asthma biologic formulations globally
Anti IgE therapy is entering an active biosimilar competition phase
Longer dosing intervals are becoming a major product differentiator
China is expanding access through approvals and domestic biologic launches
Market Trends
The Asthma Biologics market is moving from basic target expansion toward comprehensive treatment optimization across response depth, dosing burden, patient selection and continuity of care. Earlier products established anti-IgE and eosinophil-directed treatment, while IL-4R? and upstream TSLP inhibition broadened the range of addressable severe-asthma phenotypes. The latest commercial shift is toward longer dosing intervals, illustrated by the introduction of six-month anti-IL-5 administration, alongside wider adoption of prefilled devices and selected self-administration pathways. Biomarker results and clinical history are also being combined more systematically to improve initial biologic matching and subsequent switching decisions. Product value is increasingly evaluated through exacerbation reduction, oral corticosteroid sparing, lung-function preservation, pediatric applicability, treatment persistence and the potential to support clinical remission. Biosimilar entry in omalizumab is beginning to reshape the mature anti-IgE segment, increasing price competition and access while preserving the need for specialist-led treatment selection and monitoring.
Market Dynamics
Drivers
Demand for Asthma Biologics is supported by the persistent population of patients whose disease remains uncontrolled despite optimized inhaled therapies and who continue to experience recurrent exacerbations, hospitalization risk or maintenance oral corticosteroid exposure. Clinical guidance provides an increasingly structured pathway for selecting anti-IgE, anti-IL-5 or anti-IL-5R, anti-IL-4R and anti-TSLP therapies using phenotype, biomarkers, exacerbation history and relevant comorbidities. Broader pediatric approvals, expanding specialist severe-asthma networks and increasing recognition of corticosteroid-related burden are enlarging the addressable treatment population. Commercial adoption is further supported by evidence that appropriately selected biologic therapy can reduce exacerbations and improve disease control. Recent approvals of long-acting products and additional injection presentations have also widened the available treatment choices in major pharmaceutical markets.
Restraints
High acquisition costs and variable reimbursement criteria remain the principal restraints on broader biologic penetration. Access frequently depends on prior treatment failure, documented exacerbations, biomarker thresholds and specialist authorization, which can delay initiation even where clinical need is substantial. The market is also constrained by phenotype overlap, incomplete response among some patients and the absence of a universally accepted treatment sequence when several biologics appear clinically suitable. Injection logistics, cold-chain requirements and periodic monitoring add operational costs, while intravenous treatment requires infusion capacity. As biosimilars and locally manufactured anti-IgE products enter selected markets, lower prices may improve access but also intensify formulary-driven switching and place pressure on the commercial returns of established products.
Opportunities
Future opportunities are concentrated in treatment convenience, earlier patient identification and broader geographic access. Longer-interval dosing can reduce administration burden and improve persistence, while prefilled and self-administration formats can move suitable patients away from repeated facility-based injections. Upstream targets capable of treating a wider severe-asthma population create opportunities beyond narrowly defined allergic or eosinophilic phenotypes. Additional potential exists in pediatric treatment, oral corticosteroid-dependent asthma, recurrent exacerbations despite standard therapy and integrated management of asthma with related type 2 inflammatory conditions. In emerging markets, locally produced antibodies and biosimilars may reduce affordability barriers, provided that quality consistency, specialist education, biomarker testing and reimbursement pathways develop in parallel.
Challenges
The central market challenge is demonstrating durable comparative value in a field containing multiple effective mechanisms but limited direct head-to-head evidence in asthma. Treatment choice is complicated by overlapping biomarkers, changing eosinophil levels, comorbid disease and previous corticosteroid exposure, while inadequate response requires timely reassessment and switching. Manufacturers must generate long-term real-world evidence covering treatment persistence, clinical remission, safety and healthcare-resource utilization to support premium pricing and favorable reimbursement. They must also manage biologics manufacturing complexity, cold-chain reliability, pharmacovigilance and differing regional regulatory requirements. As anti-IgE biosimilars expand and new long-acting products enter, competition will increasingly center on net treatment cost, dosing convenience, clinical breadth and payer-defined outcomes rather than target novelty alone.
Industry Chain Analysis
The upstream chain for Asthma Biologics consists of antibody discovery technologies, expression cell lines, culture media, single-use bioprocess equipment, bioreactors, purification resins, filtration materials, analytical reagents, primary packaging components and cold-chain infrastructure. The midstream segment covers target validation, cell-line and process development, clinical research, regulatory registration, drug-substance manufacturing, purification, sterile fill-finish, device assembly, batch release and pharmacovigilance. Manufacturing economics are shaped by biologic yield, purification efficiency, facility utilization, quality-control intensity, formulation stability and production scale. Products with established platforms and multiple indications can distribute development and commercial infrastructure costs across a broader revenue base, while new entrants must initially absorb substantial clinical, regulatory and market-access expenditure.
Downstream distribution is centered on hospitals, severe-asthma centers, respiratory and allergy specialists, specialty pharmacies, infusion facilities and payer-authorized treatment networks. Value creation depends on identifying appropriate patients, matching biological mechanisms to phenotypes, securing reimbursement, delivering therapy consistently and documenting clinical outcomes. Specialty-care capabilities and biomarker testing therefore influence commercial performance alongside the medicine itself. Profitability is generally stronger where a product combines differentiated efficacy, convenient administration, broad age coverage and multiple approved indications, while mature anti-IgE products face increasing price and contracting pressure from biosimilars and locally manufactured alternatives.
Segment Insights
By molecule and immune target, omalizumab and omalizumab alfa constitute the most established anti-IgE segment, supported by long clinical use and the emergence of biosimilar and domestic alternatives. The IL-5 pathway represents the broadest product group in the confirmed portfolio, covering mepolizumab, reslizumab, benralizumab and depemokimab, with differentiation based on ligand versus receptor targeting, administration route and dosing frequency. Dupilumab extends treatment through IL-4R? blockade for type 2 inflammatory asthma, while tezepelumab targets the upstream epithelial cytokine TSLP and supports treatment across a broader severe-asthma phenotype. These mechanisms increasingly compete on clinical fit rather than functioning as direct substitutes for every patient.
By clinical group, allergic asthma and eosinophilic asthma remain the core biologic treatment settings, while type 2 inflammatory and broad-phenotype severe asthma are enlarging the addressable population. By administration route, subcutaneous injection is the dominant commercial format because it supports regular outpatient treatment and, for selected products and patients, home administration. Intravenous infusion remains a smaller, specialized segment associated primarily with reslizumab. The most important product-development opportunities lie in extended dosing intervals, convenient ready-to-use presentations, pediatric eligibility and therapies capable of retaining efficacy across less narrowly defined biomarker groups.
Downstream Market Opportunities
The principal downstream opportunity lies in patients with moderate-to-severe or severe asthma who remain inadequately controlled despite optimized inhaled corticosteroid-based therapy. Severe-asthma centers and specialist respiratory or allergy practices are the main adoption channels because treatment requires diagnostic confirmation, phenotype assessment, biomarker testing and follow-up evaluation. Commercial expansion can come from earlier referral of frequently exacerbating patients, improved identification of allergic and eosinophilic phenotypes, reduced long-term dependence on oral corticosteroids and wider pediatric access. Additional value can be created through coordinated management of type 2 inflammatory comorbidities, although asthma control remains the central treatment objective within this market scope. Products that reduce appointment frequency or enable appropriate self-administration are positioned to address adherence and capacity constraints in downstream care.
Regional Insights
North America represents the most commercially mature regional market for Asthma Biologics, supported by broad regulatory coverage, established severe-asthma referral networks, specialty-pharmacy infrastructure and access to the full range of major immune targets. The region also remains an important launch market for new formulations, biosimilars and extended-interval products. Europe has a similarly broad treatment portfolio, but market access varies more visibly by national health-technology assessment, reimbursement criteria and specialist prescribing rules. Biosimilar omalizumab is expected to have a more pronounced effect in price-sensitive and tender-oriented European channels.
China is among the fastest-developing access markets, driven by approvals of additional global biologics, domestic omalizumab products and expanding clinical recognition of phenotype-guided severe-asthma treatment. Mabpharm Limited and CSPC Pharmaceutical Group Limited have strengthened the local anti-IgE supply base, while recent approval of an ultra-long-acting anti-IL-5 product has broadened the available mechanism and dosing portfolio. Japan is also extending treatment access through new long-acting and pediatric approvals. Across other emerging markets, growth remains closely linked to reimbursement development, specialist capacity, biomarker availability and cold-chain coverage rather than disease prevalence alone.
Report Scope
LPI (LP Information)' newest research report, the “Asthma Biologics Industry Forecast” looks at past sales and reviews total world Asthma Biologics sales in 2025, providing a comprehensive analysis by region and market sector of projected Asthma Biologics sales for 2026 through 2032. With Asthma Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Asthma Biologics industry.
This Insight Report provides a comprehensive analysis of the global Asthma Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Asthma Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Asthma Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Asthma Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Asthma Biologics.
This report presents a comprehensive overview, market shares, and growth opportunities of Asthma Biologics market by product type, application, key players and key regions and countries.
Market Segmentation
Asthma Biologics refers to marketed monoclonal antibody medicines used as add-on maintenance therapy for patients with moderate-to-severe or severe asthma that remains uncontrolled despite optimized inhaled controller treatment. These therapies act on defined immune pathways involved in allergic and type 2 airway inflammation, principally immunoglobulin E, interleukin-5, interleukin-5 receptor alpha, interleukin-4 receptor alpha and thymic stromal lymphopoietin. Commercial products are supplied mainly as subcutaneous injections in vials, prefilled syringes or other ready-to-use presentations, while intravenous infusion remains relevant for selected anti-IL-5 therapy. Treatment selection is guided by clinical phenotype and biomarkers, including allergic sensitization, serum IgE, blood eosinophils, exacerbation history, oral corticosteroid dependence and broader type 2 inflammatory characteristics. The research scope covers approved and commercially available omalizumab, omalizumab alfa, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab and depemokimab products across adult, adolescent and pediatric asthma settings, with analysis organized by molecule, immune target, clinical phenotype and administration route.
Key Findings
The average gross profit margin of this product is 84%
Severe uncontrolled asthma remains the core commercial treatment setting
Type 2 inflammation underpins most approved biologic treatment pathways
Subcutaneous administration dominates marketed asthma biologic formulations globally
Anti IgE therapy is entering an active biosimilar competition phase
Longer dosing intervals are becoming a major product differentiator
China is expanding access through approvals and domestic biologic launches
Market Trends
The Asthma Biologics market is moving from basic target expansion toward comprehensive treatment optimization across response depth, dosing burden, patient selection and continuity of care. Earlier products established anti-IgE and eosinophil-directed treatment, while IL-4R? and upstream TSLP inhibition broadened the range of addressable severe-asthma phenotypes. The latest commercial shift is toward longer dosing intervals, illustrated by the introduction of six-month anti-IL-5 administration, alongside wider adoption of prefilled devices and selected self-administration pathways. Biomarker results and clinical history are also being combined more systematically to improve initial biologic matching and subsequent switching decisions. Product value is increasingly evaluated through exacerbation reduction, oral corticosteroid sparing, lung-function preservation, pediatric applicability, treatment persistence and the potential to support clinical remission. Biosimilar entry in omalizumab is beginning to reshape the mature anti-IgE segment, increasing price competition and access while preserving the need for specialist-led treatment selection and monitoring.
Market Dynamics
Drivers
Demand for Asthma Biologics is supported by the persistent population of patients whose disease remains uncontrolled despite optimized inhaled therapies and who continue to experience recurrent exacerbations, hospitalization risk or maintenance oral corticosteroid exposure. Clinical guidance provides an increasingly structured pathway for selecting anti-IgE, anti-IL-5 or anti-IL-5R, anti-IL-4R and anti-TSLP therapies using phenotype, biomarkers, exacerbation history and relevant comorbidities. Broader pediatric approvals, expanding specialist severe-asthma networks and increasing recognition of corticosteroid-related burden are enlarging the addressable treatment population. Commercial adoption is further supported by evidence that appropriately selected biologic therapy can reduce exacerbations and improve disease control. Recent approvals of long-acting products and additional injection presentations have also widened the available treatment choices in major pharmaceutical markets.
Restraints
High acquisition costs and variable reimbursement criteria remain the principal restraints on broader biologic penetration. Access frequently depends on prior treatment failure, documented exacerbations, biomarker thresholds and specialist authorization, which can delay initiation even where clinical need is substantial. The market is also constrained by phenotype overlap, incomplete response among some patients and the absence of a universally accepted treatment sequence when several biologics appear clinically suitable. Injection logistics, cold-chain requirements and periodic monitoring add operational costs, while intravenous treatment requires infusion capacity. As biosimilars and locally manufactured anti-IgE products enter selected markets, lower prices may improve access but also intensify formulary-driven switching and place pressure on the commercial returns of established products.
Opportunities
Future opportunities are concentrated in treatment convenience, earlier patient identification and broader geographic access. Longer-interval dosing can reduce administration burden and improve persistence, while prefilled and self-administration formats can move suitable patients away from repeated facility-based injections. Upstream targets capable of treating a wider severe-asthma population create opportunities beyond narrowly defined allergic or eosinophilic phenotypes. Additional potential exists in pediatric treatment, oral corticosteroid-dependent asthma, recurrent exacerbations despite standard therapy and integrated management of asthma with related type 2 inflammatory conditions. In emerging markets, locally produced antibodies and biosimilars may reduce affordability barriers, provided that quality consistency, specialist education, biomarker testing and reimbursement pathways develop in parallel.
Challenges
The central market challenge is demonstrating durable comparative value in a field containing multiple effective mechanisms but limited direct head-to-head evidence in asthma. Treatment choice is complicated by overlapping biomarkers, changing eosinophil levels, comorbid disease and previous corticosteroid exposure, while inadequate response requires timely reassessment and switching. Manufacturers must generate long-term real-world evidence covering treatment persistence, clinical remission, safety and healthcare-resource utilization to support premium pricing and favorable reimbursement. They must also manage biologics manufacturing complexity, cold-chain reliability, pharmacovigilance and differing regional regulatory requirements. As anti-IgE biosimilars expand and new long-acting products enter, competition will increasingly center on net treatment cost, dosing convenience, clinical breadth and payer-defined outcomes rather than target novelty alone.
Industry Chain Analysis
The upstream chain for Asthma Biologics consists of antibody discovery technologies, expression cell lines, culture media, single-use bioprocess equipment, bioreactors, purification resins, filtration materials, analytical reagents, primary packaging components and cold-chain infrastructure. The midstream segment covers target validation, cell-line and process development, clinical research, regulatory registration, drug-substance manufacturing, purification, sterile fill-finish, device assembly, batch release and pharmacovigilance. Manufacturing economics are shaped by biologic yield, purification efficiency, facility utilization, quality-control intensity, formulation stability and production scale. Products with established platforms and multiple indications can distribute development and commercial infrastructure costs across a broader revenue base, while new entrants must initially absorb substantial clinical, regulatory and market-access expenditure.
Downstream distribution is centered on hospitals, severe-asthma centers, respiratory and allergy specialists, specialty pharmacies, infusion facilities and payer-authorized treatment networks. Value creation depends on identifying appropriate patients, matching biological mechanisms to phenotypes, securing reimbursement, delivering therapy consistently and documenting clinical outcomes. Specialty-care capabilities and biomarker testing therefore influence commercial performance alongside the medicine itself. Profitability is generally stronger where a product combines differentiated efficacy, convenient administration, broad age coverage and multiple approved indications, while mature anti-IgE products face increasing price and contracting pressure from biosimilars and locally manufactured alternatives.
Segment Insights
By molecule and immune target, omalizumab and omalizumab alfa constitute the most established anti-IgE segment, supported by long clinical use and the emergence of biosimilar and domestic alternatives. The IL-5 pathway represents the broadest product group in the confirmed portfolio, covering mepolizumab, reslizumab, benralizumab and depemokimab, with differentiation based on ligand versus receptor targeting, administration route and dosing frequency. Dupilumab extends treatment through IL-4R? blockade for type 2 inflammatory asthma, while tezepelumab targets the upstream epithelial cytokine TSLP and supports treatment across a broader severe-asthma phenotype. These mechanisms increasingly compete on clinical fit rather than functioning as direct substitutes for every patient.
By clinical group, allergic asthma and eosinophilic asthma remain the core biologic treatment settings, while type 2 inflammatory and broad-phenotype severe asthma are enlarging the addressable population. By administration route, subcutaneous injection is the dominant commercial format because it supports regular outpatient treatment and, for selected products and patients, home administration. Intravenous infusion remains a smaller, specialized segment associated primarily with reslizumab. The most important product-development opportunities lie in extended dosing intervals, convenient ready-to-use presentations, pediatric eligibility and therapies capable of retaining efficacy across less narrowly defined biomarker groups.
Downstream Market Opportunities
The principal downstream opportunity lies in patients with moderate-to-severe or severe asthma who remain inadequately controlled despite optimized inhaled corticosteroid-based therapy. Severe-asthma centers and specialist respiratory or allergy practices are the main adoption channels because treatment requires diagnostic confirmation, phenotype assessment, biomarker testing and follow-up evaluation. Commercial expansion can come from earlier referral of frequently exacerbating patients, improved identification of allergic and eosinophilic phenotypes, reduced long-term dependence on oral corticosteroids and wider pediatric access. Additional value can be created through coordinated management of type 2 inflammatory comorbidities, although asthma control remains the central treatment objective within this market scope. Products that reduce appointment frequency or enable appropriate self-administration are positioned to address adherence and capacity constraints in downstream care.
Regional Insights
North America represents the most commercially mature regional market for Asthma Biologics, supported by broad regulatory coverage, established severe-asthma referral networks, specialty-pharmacy infrastructure and access to the full range of major immune targets. The region also remains an important launch market for new formulations, biosimilars and extended-interval products. Europe has a similarly broad treatment portfolio, but market access varies more visibly by national health-technology assessment, reimbursement criteria and specialist prescribing rules. Biosimilar omalizumab is expected to have a more pronounced effect in price-sensitive and tender-oriented European channels.
China is among the fastest-developing access markets, driven by approvals of additional global biologics, domestic omalizumab products and expanding clinical recognition of phenotype-guided severe-asthma treatment. Mabpharm Limited and CSPC Pharmaceutical Group Limited have strengthened the local anti-IgE supply base, while recent approval of an ultra-long-acting anti-IL-5 product has broadened the available mechanism and dosing portfolio. Japan is also extending treatment access through new long-acting and pediatric approvals. Across other emerging markets, growth remains closely linked to reimbursement development, specialist capacity, biomarker availability and cold-chain coverage rather than disease prevalence alone.
Report Scope
LPI (LP Information)' newest research report, the “Asthma Biologics Industry Forecast” looks at past sales and reviews total world Asthma Biologics sales in 2025, providing a comprehensive analysis by region and market sector of projected Asthma Biologics sales for 2026 through 2032. With Asthma Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Asthma Biologics industry.
This Insight Report provides a comprehensive analysis of the global Asthma Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Asthma Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Asthma Biologics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Asthma Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Asthma Biologics.
This report presents a comprehensive overview, market shares, and growth opportunities of Asthma Biologics market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- Omalizumab
- Mepolizumab
- Reslizumab
- Benralizumab
- Dupilumab
- Other
Segmentation by Route of Administration:
- Subcutaneous Injection
- Intravenous Infusion
Segmentation by Antibodies:
- Anti-IgE Monoclonal Antibodies
- Anti-IL-5 Monoclonal Antibodies
- Anti-IL-5 Receptor Alpha Monoclonal Antibodies
Segmentation by Application:
- Allergic Asthma Biologics
- Eosinophilic Asthma Biologics
- Other
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Roche
- GSK
- AstraZeneca
- Teva Pharmaceutical
- Sanofi
- Regeneron Pharmaceuticals
- Amgen
- Celltrion
- Mabpharm Limited
- CSPC Pharmaceutical
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Asthma Biologics Market Size (2021-2032)
2.1.2 Asthma Biologics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Asthma Biologics by Country/Region (2021, 2025 & 2032)
2.2 Asthma Biologics Segment by Type
2.2.1 Omalizumab
2.2.2 Mepolizumab
2.2.3 Reslizumab
2.2.4 Benralizumab
2.2.5 Dupilumab
2.2.6 Other
2.2.7 Asthma Biologics Market Size by Type
2.2.7.1 Asthma Biologics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Asthma Biologics Market Size Market Share by Type (2021-2026)
2.3 Asthma Biologics Segment by Route of Administration
2.3.1 Subcutaneous Injection
2.3.2 Intravenous Infusion
2.3.3 Asthma Biologics Market Size by Route of Administration
2.3.3.1 Asthma Biologics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.3.3.2 Global Asthma Biologics Market Size Market Share by Route of Administration (2021-2026)
2.4 Asthma Biologics Segment by Antibodies
2.4.1 Anti-IgE Monoclonal Antibodies
2.4.2 Anti-IL-5 Monoclonal Antibodies
2.4.3 Anti-IL-5 Receptor Alpha Monoclonal Antibodies
2.4.4 Asthma Biologics Market Size by Antibodies
2.4.4.1 Asthma Biologics Market Size CAGR by Antibodies (2021 VS 2025 VS 2032)
2.4.4.2 Global Asthma Biologics Market Size Market Share by Antibodies (2021-2026)
2.5 Asthma Biologics Segment by Application
2.5.1 Allergic Asthma Biologics
2.5.2 Eosinophilic Asthma Biologics
2.5.3 Other
2.5.4 Asthma Biologics Market Size by Application
2.5.4.1 Asthma Biologics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Asthma Biologics Market Size Market Share by Application (2021-2026)
3 ASTHMA BIOLOGICS MARKET SIZE BY PLAYER
3.1 Asthma Biologics Market Size Market Share by Player
3.1.1 Global Asthma Biologics Revenue by Player (2021-2026)
3.1.2 Global Asthma Biologics Revenue Market Share by Player (2021-2026)
3.2 Global Asthma Biologics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ASTHMA BIOLOGICS BY REGION
4.1 Asthma Biologics Market Size by Region (2021-2026)
4.2 Global Asthma Biologics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Asthma Biologics Market Size Growth (2021-2026)
4.4 APAC Asthma Biologics Market Size Growth (2021-2026)
4.5 Europe Asthma Biologics Market Size Growth (2021-2026)
4.6 Middle East & Africa Asthma Biologics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Asthma Biologics Market Size by Country (2021-2026)
5.2 Americas Asthma Biologics Market Size by Type (2021-2026)
5.3 Americas Asthma Biologics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Asthma Biologics Market Size by Region (2021-2026)
6.2 APAC Asthma Biologics Market Size by Type (2021-2026)
6.3 APAC Asthma Biologics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Asthma Biologics Market Size by Country (2021-2026)
7.2 Europe Asthma Biologics Market Size by Type (2021-2026)
7.3 Europe Asthma Biologics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Asthma Biologics by Region (2021-2026)
8.2 Middle East & Africa Asthma Biologics Market Size by Type (2021-2026)
8.3 Middle East & Africa Asthma Biologics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ASTHMA BIOLOGICS MARKET FORECAST
10.1 Global Asthma Biologics Forecast by Region (2027-2032)
10.1.1 Global Asthma Biologics Forecast by Region (2027-2032)
10.1.2 Americas Asthma Biologics Forecast
10.1.3 APAC Asthma Biologics Forecast
10.1.4 Europe Asthma Biologics Forecast
10.1.5 Middle East & Africa Asthma Biologics Forecast
10.2 Americas Asthma Biologics Forecast by Country (2027-2032)
10.2.1 United States Market Asthma Biologics Forecast
10.2.2 Canada Market Asthma Biologics Forecast
10.2.3 Mexico Market Asthma Biologics Forecast
10.2.4 Brazil Market Asthma Biologics Forecast
10.3 APAC Asthma Biologics Forecast by Region (2027-2032)
10.3.1 China Asthma Biologics Market Forecast
10.3.2 Japan Market Asthma Biologics Forecast
10.3.3 Korea Market Asthma Biologics Forecast
10.3.4 Southeast Asia Market Asthma Biologics Forecast
10.3.5 India Market Asthma Biologics Forecast
10.3.6 Australia Market Asthma Biologics Forecast
10.4 Europe Asthma Biologics Forecast by Country (2027-2032)
10.4.1 Germany Market Asthma Biologics Forecast
10.4.2 France Market Asthma Biologics Forecast
10.4.3 UK Market Asthma Biologics Forecast
10.4.4 Italy Market Asthma Biologics Forecast
10.4.5 Russia Market Asthma Biologics Forecast
10.5 Middle East & Africa Asthma Biologics Forecast by Region (2027-2032)
10.5.1 Egypt Market Asthma Biologics Forecast
10.5.2 South Africa Market Asthma Biologics Forecast
10.5.3 Israel Market Asthma Biologics Forecast
10.5.4 Turkey Market Asthma Biologics Forecast
10.6 Global Asthma Biologics Forecast by Type (2027-2032)
10.7 Global Asthma Biologics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Asthma Biologics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Asthma Biologics Product Offered
11.1.3 Novartis Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Asthma Biologics Product Offered
11.2.3 Roche Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 GSK
11.3.1 GSK Company Information
11.3.2 GSK Asthma Biologics Product Offered
11.3.3 GSK Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 GSK Main Business Overview
11.3.5 GSK Latest Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Asthma Biologics Product Offered
11.4.3 AstraZeneca Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 AstraZeneca Main Business Overview
11.4.5 AstraZeneca Latest Developments
11.5 Teva Pharmaceutical
11.5.1 Teva Pharmaceutical Company Information
11.5.2 Teva Pharmaceutical Asthma Biologics Product Offered
11.5.3 Teva Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Teva Pharmaceutical Main Business Overview
11.5.5 Teva Pharmaceutical Latest Developments
11.6 Sanofi
11.6.1 Sanofi Company Information
11.6.2 Sanofi Asthma Biologics Product Offered
11.6.3 Sanofi Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sanofi Main Business Overview
11.6.5 Sanofi Latest Developments
11.7 Regeneron Pharmaceuticals
11.7.1 Regeneron Pharmaceuticals Company Information
11.7.2 Regeneron Pharmaceuticals Asthma Biologics Product Offered
11.7.3 Regeneron Pharmaceuticals Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Regeneron Pharmaceuticals Main Business Overview
11.7.5 Regeneron Pharmaceuticals Latest Developments
11.8 Amgen
11.8.1 Amgen Company Information
11.8.2 Amgen Asthma Biologics Product Offered
11.8.3 Amgen Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Amgen Main Business Overview
11.8.5 Amgen Latest Developments
11.9 Celltrion
11.9.1 Celltrion Company Information
11.9.2 Celltrion Asthma Biologics Product Offered
11.9.3 Celltrion Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Celltrion Main Business Overview
11.9.5 Celltrion Latest Developments
11.10 Mabpharm Limited
11.10.1 Mabpharm Limited Company Information
11.10.2 Mabpharm Limited Asthma Biologics Product Offered
11.10.3 Mabpharm Limited Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Mabpharm Limited Main Business Overview
11.10.5 Mabpharm Limited Latest Developments
11.11 CSPC Pharmaceutical
11.11.1 CSPC Pharmaceutical Company Information
11.11.2 CSPC Pharmaceutical Asthma Biologics Product Offered
11.11.3 CSPC Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 CSPC Pharmaceutical Main Business Overview
11.11.5 CSPC Pharmaceutical Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Asthma Biologics Market Size (2021-2032)
2.1.2 Asthma Biologics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Asthma Biologics by Country/Region (2021, 2025 & 2032)
2.2 Asthma Biologics Segment by Type
2.2.1 Omalizumab
2.2.2 Mepolizumab
2.2.3 Reslizumab
2.2.4 Benralizumab
2.2.5 Dupilumab
2.2.6 Other
2.2.7 Asthma Biologics Market Size by Type
2.2.7.1 Asthma Biologics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Asthma Biologics Market Size Market Share by Type (2021-2026)
2.3 Asthma Biologics Segment by Route of Administration
2.3.1 Subcutaneous Injection
2.3.2 Intravenous Infusion
2.3.3 Asthma Biologics Market Size by Route of Administration
2.3.3.1 Asthma Biologics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.3.3.2 Global Asthma Biologics Market Size Market Share by Route of Administration (2021-2026)
2.4 Asthma Biologics Segment by Antibodies
2.4.1 Anti-IgE Monoclonal Antibodies
2.4.2 Anti-IL-5 Monoclonal Antibodies
2.4.3 Anti-IL-5 Receptor Alpha Monoclonal Antibodies
2.4.4 Asthma Biologics Market Size by Antibodies
2.4.4.1 Asthma Biologics Market Size CAGR by Antibodies (2021 VS 2025 VS 2032)
2.4.4.2 Global Asthma Biologics Market Size Market Share by Antibodies (2021-2026)
2.5 Asthma Biologics Segment by Application
2.5.1 Allergic Asthma Biologics
2.5.2 Eosinophilic Asthma Biologics
2.5.3 Other
2.5.4 Asthma Biologics Market Size by Application
2.5.4.1 Asthma Biologics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.4.2 Global Asthma Biologics Market Size Market Share by Application (2021-2026)
3 ASTHMA BIOLOGICS MARKET SIZE BY PLAYER
3.1 Asthma Biologics Market Size Market Share by Player
3.1.1 Global Asthma Biologics Revenue by Player (2021-2026)
3.1.2 Global Asthma Biologics Revenue Market Share by Player (2021-2026)
3.2 Global Asthma Biologics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ASTHMA BIOLOGICS BY REGION
4.1 Asthma Biologics Market Size by Region (2021-2026)
4.2 Global Asthma Biologics Annual Revenue by Country/Region (2021-2026)
4.3 Americas Asthma Biologics Market Size Growth (2021-2026)
4.4 APAC Asthma Biologics Market Size Growth (2021-2026)
4.5 Europe Asthma Biologics Market Size Growth (2021-2026)
4.6 Middle East & Africa Asthma Biologics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Asthma Biologics Market Size by Country (2021-2026)
5.2 Americas Asthma Biologics Market Size by Type (2021-2026)
5.3 Americas Asthma Biologics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Asthma Biologics Market Size by Region (2021-2026)
6.2 APAC Asthma Biologics Market Size by Type (2021-2026)
6.3 APAC Asthma Biologics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Asthma Biologics Market Size by Country (2021-2026)
7.2 Europe Asthma Biologics Market Size by Type (2021-2026)
7.3 Europe Asthma Biologics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Asthma Biologics by Region (2021-2026)
8.2 Middle East & Africa Asthma Biologics Market Size by Type (2021-2026)
8.3 Middle East & Africa Asthma Biologics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ASTHMA BIOLOGICS MARKET FORECAST
10.1 Global Asthma Biologics Forecast by Region (2027-2032)
10.1.1 Global Asthma Biologics Forecast by Region (2027-2032)
10.1.2 Americas Asthma Biologics Forecast
10.1.3 APAC Asthma Biologics Forecast
10.1.4 Europe Asthma Biologics Forecast
10.1.5 Middle East & Africa Asthma Biologics Forecast
10.2 Americas Asthma Biologics Forecast by Country (2027-2032)
10.2.1 United States Market Asthma Biologics Forecast
10.2.2 Canada Market Asthma Biologics Forecast
10.2.3 Mexico Market Asthma Biologics Forecast
10.2.4 Brazil Market Asthma Biologics Forecast
10.3 APAC Asthma Biologics Forecast by Region (2027-2032)
10.3.1 China Asthma Biologics Market Forecast
10.3.2 Japan Market Asthma Biologics Forecast
10.3.3 Korea Market Asthma Biologics Forecast
10.3.4 Southeast Asia Market Asthma Biologics Forecast
10.3.5 India Market Asthma Biologics Forecast
10.3.6 Australia Market Asthma Biologics Forecast
10.4 Europe Asthma Biologics Forecast by Country (2027-2032)
10.4.1 Germany Market Asthma Biologics Forecast
10.4.2 France Market Asthma Biologics Forecast
10.4.3 UK Market Asthma Biologics Forecast
10.4.4 Italy Market Asthma Biologics Forecast
10.4.5 Russia Market Asthma Biologics Forecast
10.5 Middle East & Africa Asthma Biologics Forecast by Region (2027-2032)
10.5.1 Egypt Market Asthma Biologics Forecast
10.5.2 South Africa Market Asthma Biologics Forecast
10.5.3 Israel Market Asthma Biologics Forecast
10.5.4 Turkey Market Asthma Biologics Forecast
10.6 Global Asthma Biologics Forecast by Type (2027-2032)
10.7 Global Asthma Biologics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Asthma Biologics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Asthma Biologics Product Offered
11.1.3 Novartis Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Asthma Biologics Product Offered
11.2.3 Roche Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 GSK
11.3.1 GSK Company Information
11.3.2 GSK Asthma Biologics Product Offered
11.3.3 GSK Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 GSK Main Business Overview
11.3.5 GSK Latest Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Asthma Biologics Product Offered
11.4.3 AstraZeneca Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 AstraZeneca Main Business Overview
11.4.5 AstraZeneca Latest Developments
11.5 Teva Pharmaceutical
11.5.1 Teva Pharmaceutical Company Information
11.5.2 Teva Pharmaceutical Asthma Biologics Product Offered
11.5.3 Teva Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Teva Pharmaceutical Main Business Overview
11.5.5 Teva Pharmaceutical Latest Developments
11.6 Sanofi
11.6.1 Sanofi Company Information
11.6.2 Sanofi Asthma Biologics Product Offered
11.6.3 Sanofi Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Sanofi Main Business Overview
11.6.5 Sanofi Latest Developments
11.7 Regeneron Pharmaceuticals
11.7.1 Regeneron Pharmaceuticals Company Information
11.7.2 Regeneron Pharmaceuticals Asthma Biologics Product Offered
11.7.3 Regeneron Pharmaceuticals Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Regeneron Pharmaceuticals Main Business Overview
11.7.5 Regeneron Pharmaceuticals Latest Developments
11.8 Amgen
11.8.1 Amgen Company Information
11.8.2 Amgen Asthma Biologics Product Offered
11.8.3 Amgen Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Amgen Main Business Overview
11.8.5 Amgen Latest Developments
11.9 Celltrion
11.9.1 Celltrion Company Information
11.9.2 Celltrion Asthma Biologics Product Offered
11.9.3 Celltrion Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Celltrion Main Business Overview
11.9.5 Celltrion Latest Developments
11.10 Mabpharm Limited
11.10.1 Mabpharm Limited Company Information
11.10.2 Mabpharm Limited Asthma Biologics Product Offered
11.10.3 Mabpharm Limited Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Mabpharm Limited Main Business Overview
11.10.5 Mabpharm Limited Latest Developments
11.11 CSPC Pharmaceutical
11.11.1 CSPC Pharmaceutical Company Information
11.11.2 CSPC Pharmaceutical Asthma Biologics Product Offered
11.11.3 CSPC Pharmaceutical Asthma Biologics Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 CSPC Pharmaceutical Main Business Overview
11.11.5 CSPC Pharmaceutical Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Asthma Biologics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Asthma Biologics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Omalizumab
Table 4. Major Players of Mepolizumab
Table 5. Major Players of Reslizumab
Table 6. Major Players of Benralizumab
Table 7. Major Players of Dupilumab
Table 8. Major Players of Other
Table 9. Asthma Biologics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Asthma Biologics Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Subcutaneous Injection
Table 13. Major Players of Intravenous Infusion
Table 14. Asthma Biologics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Asthma Biologics Market Size by Route of Administration (2021-2026) & ($ millions)
Table 16. Global Asthma Biologics Market Size Market Share by Route of Administration (2021-2026)
Table 17. Major Players of Anti-IgE Monoclonal Antibodies
Table 18. Major Players of Anti-IL-5 Monoclonal Antibodies
Table 19. Major Players of Anti-IL-5 Receptor Alpha Monoclonal Antibodies
Table 20. Asthma Biologics Market Size CAGR by Antibodies (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Asthma Biologics Market Size by Antibodies (2021-2026) & ($ millions)
Table 22. Global Asthma Biologics Market Size Market Share by Antibodies (2021-2026)
Table 23. Asthma Biologics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 25. Global Asthma Biologics Market Size Market Share by Application (2021-2026)
Table 26. Global Asthma Biologics Revenue by Player (2021-2026) & ($ millions)
Table 27. Global Asthma Biologics Revenue Market Share by Player (2021-2026)
Table 28. Asthma Biologics Key Players Head office and Products Offered
Table 29. Asthma Biologics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Asthma Biologics Market Size by Region (2021-2026) & ($ millions)
Table 33. Global Asthma Biologics Market Size Market Share by Region (2021-2026)
Table 34. Global Asthma Biologics Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Asthma Biologics Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Asthma Biologics Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas Asthma Biologics Market Size Market Share by Country (2021-2026)
Table 38. Americas Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas Asthma Biologics Market Size Market Share by Type (2021-2026)
Table 40. Americas Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas Asthma Biologics Market Size Market Share by Application (2021-2026)
Table 42. APAC Asthma Biologics Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC Asthma Biologics Market Size Market Share by Region (2021-2026)
Table 44. APAC Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe Asthma Biologics Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe Asthma Biologics Market Size Market Share by Country (2021-2026)
Table 48. Europe Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa Asthma Biologics Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of Asthma Biologics
Table 54. Key Market Challenges & Risks of Asthma Biologics
Table 55. Key Industry Trends of Asthma Biologics
Table 56. Global Asthma Biologics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global Asthma Biologics Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global Asthma Biologics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global Asthma Biologics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. Novartis Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 61. Novartis Asthma Biologics Product Offered
Table 62. Novartis Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Novartis Main Business
Table 64. Novartis Latest Developments
Table 65. Roche Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 66. Roche Asthma Biologics Product Offered
Table 67. Roche Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Roche Main Business
Table 69. Roche Latest Developments
Table 70. GSK Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 71. GSK Asthma Biologics Product Offered
Table 72. GSK Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. GSK Main Business
Table 74. GSK Latest Developments
Table 75. AstraZeneca Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 76. AstraZeneca Asthma Biologics Product Offered
Table 77. AstraZeneca Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. AstraZeneca Main Business
Table 79. AstraZeneca Latest Developments
Table 80. Teva Pharmaceutical Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 81. Teva Pharmaceutical Asthma Biologics Product Offered
Table 82. Teva Pharmaceutical Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Teva Pharmaceutical Main Business
Table 84. Teva Pharmaceutical Latest Developments
Table 85. Sanofi Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 86. Sanofi Asthma Biologics Product Offered
Table 87. Sanofi Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Sanofi Main Business
Table 89. Sanofi Latest Developments
Table 90. Regeneron Pharmaceuticals Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 91. Regeneron Pharmaceuticals Asthma Biologics Product Offered
Table 92. Regeneron Pharmaceuticals Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Regeneron Pharmaceuticals Main Business
Table 94. Regeneron Pharmaceuticals Latest Developments
Table 95. Amgen Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 96. Amgen Asthma Biologics Product Offered
Table 97. Amgen Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Amgen Main Business
Table 99. Amgen Latest Developments
Table 100. Celltrion Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 101. Celltrion Asthma Biologics Product Offered
Table 102. Celltrion Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Celltrion Main Business
Table 104. Celltrion Latest Developments
Table 105. Mabpharm Limited Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 106. Mabpharm Limited Asthma Biologics Product Offered
Table 107. Mabpharm Limited Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Mabpharm Limited Main Business
Table 109. Mabpharm Limited Latest Developments
Table 110. CSPC Pharmaceutical Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 111. CSPC Pharmaceutical Asthma Biologics Product Offered
Table 112. CSPC Pharmaceutical Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. CSPC Pharmaceutical Main Business
Table 114. CSPC Pharmaceutical Latest Developments
Table 1. Asthma Biologics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Asthma Biologics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Omalizumab
Table 4. Major Players of Mepolizumab
Table 5. Major Players of Reslizumab
Table 6. Major Players of Benralizumab
Table 7. Major Players of Dupilumab
Table 8. Major Players of Other
Table 9. Asthma Biologics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Asthma Biologics Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Subcutaneous Injection
Table 13. Major Players of Intravenous Infusion
Table 14. Asthma Biologics Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Asthma Biologics Market Size by Route of Administration (2021-2026) & ($ millions)
Table 16. Global Asthma Biologics Market Size Market Share by Route of Administration (2021-2026)
Table 17. Major Players of Anti-IgE Monoclonal Antibodies
Table 18. Major Players of Anti-IL-5 Monoclonal Antibodies
Table 19. Major Players of Anti-IL-5 Receptor Alpha Monoclonal Antibodies
Table 20. Asthma Biologics Market Size CAGR by Antibodies (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Asthma Biologics Market Size by Antibodies (2021-2026) & ($ millions)
Table 22. Global Asthma Biologics Market Size Market Share by Antibodies (2021-2026)
Table 23. Asthma Biologics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 25. Global Asthma Biologics Market Size Market Share by Application (2021-2026)
Table 26. Global Asthma Biologics Revenue by Player (2021-2026) & ($ millions)
Table 27. Global Asthma Biologics Revenue Market Share by Player (2021-2026)
Table 28. Asthma Biologics Key Players Head office and Products Offered
Table 29. Asthma Biologics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Asthma Biologics Market Size by Region (2021-2026) & ($ millions)
Table 33. Global Asthma Biologics Market Size Market Share by Region (2021-2026)
Table 34. Global Asthma Biologics Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Asthma Biologics Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Asthma Biologics Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas Asthma Biologics Market Size Market Share by Country (2021-2026)
Table 38. Americas Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas Asthma Biologics Market Size Market Share by Type (2021-2026)
Table 40. Americas Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas Asthma Biologics Market Size Market Share by Application (2021-2026)
Table 42. APAC Asthma Biologics Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC Asthma Biologics Market Size Market Share by Region (2021-2026)
Table 44. APAC Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe Asthma Biologics Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe Asthma Biologics Market Size Market Share by Country (2021-2026)
Table 48. Europe Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa Asthma Biologics Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa Asthma Biologics Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa Asthma Biologics Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of Asthma Biologics
Table 54. Key Market Challenges & Risks of Asthma Biologics
Table 55. Key Industry Trends of Asthma Biologics
Table 56. Global Asthma Biologics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global Asthma Biologics Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global Asthma Biologics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global Asthma Biologics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. Novartis Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 61. Novartis Asthma Biologics Product Offered
Table 62. Novartis Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Novartis Main Business
Table 64. Novartis Latest Developments
Table 65. Roche Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 66. Roche Asthma Biologics Product Offered
Table 67. Roche Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Roche Main Business
Table 69. Roche Latest Developments
Table 70. GSK Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 71. GSK Asthma Biologics Product Offered
Table 72. GSK Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. GSK Main Business
Table 74. GSK Latest Developments
Table 75. AstraZeneca Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 76. AstraZeneca Asthma Biologics Product Offered
Table 77. AstraZeneca Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. AstraZeneca Main Business
Table 79. AstraZeneca Latest Developments
Table 80. Teva Pharmaceutical Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 81. Teva Pharmaceutical Asthma Biologics Product Offered
Table 82. Teva Pharmaceutical Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Teva Pharmaceutical Main Business
Table 84. Teva Pharmaceutical Latest Developments
Table 85. Sanofi Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 86. Sanofi Asthma Biologics Product Offered
Table 87. Sanofi Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Sanofi Main Business
Table 89. Sanofi Latest Developments
Table 90. Regeneron Pharmaceuticals Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 91. Regeneron Pharmaceuticals Asthma Biologics Product Offered
Table 92. Regeneron Pharmaceuticals Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Regeneron Pharmaceuticals Main Business
Table 94. Regeneron Pharmaceuticals Latest Developments
Table 95. Amgen Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 96. Amgen Asthma Biologics Product Offered
Table 97. Amgen Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Amgen Main Business
Table 99. Amgen Latest Developments
Table 100. Celltrion Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 101. Celltrion Asthma Biologics Product Offered
Table 102. Celltrion Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Celltrion Main Business
Table 104. Celltrion Latest Developments
Table 105. Mabpharm Limited Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 106. Mabpharm Limited Asthma Biologics Product Offered
Table 107. Mabpharm Limited Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Mabpharm Limited Main Business
Table 109. Mabpharm Limited Latest Developments
Table 110. CSPC Pharmaceutical Details, Company Type, Asthma Biologics Area Served and Its Competitors
Table 111. CSPC Pharmaceutical Asthma Biologics Product Offered
Table 112. CSPC Pharmaceutical Asthma Biologics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. CSPC Pharmaceutical Main Business
Table 114. CSPC Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Asthma Biologics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Asthma Biologics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Asthma Biologics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Asthma Biologics Sales Market Share by Country/Region (2025)
Figure 8. Asthma Biologics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Asthma Biologics Market Size Market Share by Type in 2025
Figure 10. Global Asthma Biologics Market Size Market Share by Route of Administration in 2025
Figure 11. Global Asthma Biologics Market Size Market Share by Antibodies in 2025
Figure 12. Asthma Biologics in Allergic Asthma Biologics
Figure 13. Global Asthma Biologics Market: Allergic Asthma Biologics (2021-2026) & ($ millions)
Figure 14. Asthma Biologics in Eosinophilic Asthma Biologics
Figure 15. Global Asthma Biologics Market: Eosinophilic Asthma Biologics (2021-2026) & ($ millions)
Figure 16. Asthma Biologics in Other
Figure 17. Global Asthma Biologics Market: Other (2021-2026) & ($ millions)
Figure 18. Global Asthma Biologics Market Size Market Share by Application in 2025
Figure 19. Global Asthma Biologics Revenue Market Share by Player in 2025
Figure 20. Global Asthma Biologics Market Size Market Share by Region (2021-2026)
Figure 21. Americas Asthma Biologics Market Size 2021-2026 ($ millions)
Figure 22. APAC Asthma Biologics Market Size 2021-2026 ($ millions)
Figure 23. Europe Asthma Biologics Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Asthma Biologics Market Size 2021-2026 ($ millions)
Figure 25. Americas Asthma Biologics Value Market Share by Country in 2025
Figure 26. United States Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Asthma Biologics Market Size Market Share by Region in 2025
Figure 31. APAC Asthma Biologics Market Size Market Share by Type (2021-2026)
Figure 32. APAC Asthma Biologics Market Size Market Share by Application (2021-2026)
Figure 33. China Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 37. India Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Asthma Biologics Market Size Market Share by Country in 2025
Figure 40. Europe Asthma Biologics Market Size Market Share by Type (2021-2026)
Figure 41. Europe Asthma Biologics Market Size Market Share by Application (2021-2026)
Figure 42. Germany Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 43. France Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Asthma Biologics Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Asthma Biologics Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Asthma Biologics Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 56. APAC Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 57. Europe Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 59. United States Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 60. Canada Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 61. Mexico Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 62. Brazil Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 63. China Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 64. Japan Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 65. Korea Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 67. India Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 68. Australia Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 69. Germany Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 70. France Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 71. UK Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 72. Italy Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 73. Russia Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 74. Egypt Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 75. South Africa Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 76. Israel Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 77. Turkey Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 78. Global Asthma Biologics Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Asthma Biologics Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 1. Asthma Biologics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Asthma Biologics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Asthma Biologics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Asthma Biologics Sales Market Share by Country/Region (2025)
Figure 8. Asthma Biologics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Asthma Biologics Market Size Market Share by Type in 2025
Figure 10. Global Asthma Biologics Market Size Market Share by Route of Administration in 2025
Figure 11. Global Asthma Biologics Market Size Market Share by Antibodies in 2025
Figure 12. Asthma Biologics in Allergic Asthma Biologics
Figure 13. Global Asthma Biologics Market: Allergic Asthma Biologics (2021-2026) & ($ millions)
Figure 14. Asthma Biologics in Eosinophilic Asthma Biologics
Figure 15. Global Asthma Biologics Market: Eosinophilic Asthma Biologics (2021-2026) & ($ millions)
Figure 16. Asthma Biologics in Other
Figure 17. Global Asthma Biologics Market: Other (2021-2026) & ($ millions)
Figure 18. Global Asthma Biologics Market Size Market Share by Application in 2025
Figure 19. Global Asthma Biologics Revenue Market Share by Player in 2025
Figure 20. Global Asthma Biologics Market Size Market Share by Region (2021-2026)
Figure 21. Americas Asthma Biologics Market Size 2021-2026 ($ millions)
Figure 22. APAC Asthma Biologics Market Size 2021-2026 ($ millions)
Figure 23. Europe Asthma Biologics Market Size 2021-2026 ($ millions)
Figure 24. Middle East & Africa Asthma Biologics Market Size 2021-2026 ($ millions)
Figure 25. Americas Asthma Biologics Value Market Share by Country in 2025
Figure 26. United States Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 27. Canada Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 28. Mexico Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 29. Brazil Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 30. APAC Asthma Biologics Market Size Market Share by Region in 2025
Figure 31. APAC Asthma Biologics Market Size Market Share by Type (2021-2026)
Figure 32. APAC Asthma Biologics Market Size Market Share by Application (2021-2026)
Figure 33. China Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 34. Japan Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 35. South Korea Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 36. Southeast Asia Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 37. India Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 38. Australia Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 39. Europe Asthma Biologics Market Size Market Share by Country in 2025
Figure 40. Europe Asthma Biologics Market Size Market Share by Type (2021-2026)
Figure 41. Europe Asthma Biologics Market Size Market Share by Application (2021-2026)
Figure 42. Germany Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 43. France Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 44. UK Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 45. Italy Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 46. Russia Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 47. Middle East & Africa Asthma Biologics Market Size Market Share by Region (2021-2026)
Figure 48. Middle East & Africa Asthma Biologics Market Size Market Share by Type (2021-2026)
Figure 49. Middle East & Africa Asthma Biologics Market Size Market Share by Application (2021-2026)
Figure 50. Egypt Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 51. South Africa Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 52. Israel Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 53. Turkey Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 54. GCC Countries Asthma Biologics Market Size Growth 2021-2026 ($ millions)
Figure 55. Americas Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 56. APAC Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 57. Europe Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 58. Middle East & Africa Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 59. United States Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 60. Canada Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 61. Mexico Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 62. Brazil Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 63. China Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 64. Japan Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 65. Korea Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 66. Southeast Asia Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 67. India Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 68. Australia Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 69. Germany Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 70. France Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 71. UK Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 72. Italy Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 73. Russia Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 74. Egypt Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 75. South Africa Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 76. Israel Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 77. Turkey Asthma Biologics Market Size 2027-2032 ($ millions)
Figure 78. Global Asthma Biologics Market Size Market Share Forecast by Type (2027-2032)
Figure 79. Global Asthma Biologics Market Size Market Share Forecast by Application (2027-2032)
Figure 80. GCC Countries Asthma Biologics Market Size 2027-2032 ($ millions)
